Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

NHS England

This public procurement record has 8 releases in its history.

Award

21 Jul 2026 at 11:16

UK7 - Contract Details Notice
AwardUpdate

09 Jul 2026 at 15:45

UK6 - Contract Award Notice
Award

23 Jun 2026 at 12:33

UK6 - Contract Award Notice
Tender

17 Mar 2026 at 12:14

UK4 - Tender Notice
PlanningUpdate

13 Mar 2026 at 15:08

UK2 - Preliminary Market Engagement Notice
Planning

13 Jan 2026 at 09:57

UK2 - Preliminary Market Engagement Notice
PlanningUpdate

03 Jun 2025 at 12:41

UK1 - Pipeline Notice
Planning

22 May 2025 at 09:34

UK1 - Pipeline Notice
Summary of the contracting process

NHS England procured pharmaceutical products through the NHS Branded Medicines Tranche A framework. The scope covers eight therapeutic areas: erythropoiesis-stimulating agents, granulocyte-colony stimulating factor, insulin analogues, multiple sclerosis medicines, parenteral iron, severe asthma medicines, severe asthma interleukin inhibitors and teriparatide. Lot 1 covers branded medicines for the North of England and the Midlands and East, while Lot 2 covers natalizumab for London and the South of England. The framework serves NHS participating authorities and pharmacy purchasing points, with delivery across England. It is a goods procurement for pharmaceutical products, suitable for SMEs. NHS England is the buying organisation and framework users may include authorities and pharmacy purchasing points identified in the procurement documents.

The procurement was awarded through an open procedure and is now contractually active. It uses an open framework with reopening of competition. Lot 1 was awarded on 15 June 2026 to 25 pharmaceutical suppliers, including Sanofi, Accord-UK, Amgen, Bayer, Biogen, Chugai, Cipla, Eli Lilly, GSK, Merck, Novo Nordisk, Pfizer, Roche, Sandoz, Teva, Viatris and Vifor Pharma; its contract was signed on 6 July 2026. The Lot 1 contract is worth £665,389,588 excluding VAT and runs from 1 September 2026 to 31 August 2028, with extensions up to 31 August 2030. Lot 2 was awarded on 15 June 2026 to Biogen Idec and Sandoz, signed on 6 July 2026, and is worth £35,312,548 excluding VAT. It runs to 31 August 2027, with extensions up to 31 August 2028. Price was not the only award criterion; all criteria were in the procurement documents.

This award demonstrates sustained NHS demand for branded medicines across multiple specialist therapeutic categories and at substantial framework scale. It shows that the relevant supplier market includes both large pharmaceutical companies and smaller specialist businesses: six SMEs submitted final bids for Lot 1, and the lots were marked as suitable for SMEs. A credible future competitor would need a branded-medicines portfolio aligned to one or more of the eight categories, reliable supply capability across the relevant NHS regions, and the commercial capacity to operate within a multi-supplier framework. Suppliers should also be prepared for competition to reopen under the framework, since the arrangements use reopening of competition. Lot 2 indicates particular demand for natalizumab in London and the South of England, with Biogen Idec and Sandoz selected for that requirement.

How relevant is this notice?

Notice Information

Notice Title

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

Notice Description

NHS Branded Framework Agreement - Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority's discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Lot Information

CM/PHR/25/5730/01 - Tranche B for NOFE and MAE

Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority's discretion for a further 24 months.

Options: CM/PHR/25/5730/01 - Lot 1 - Tranche A for North of England and Midlands & East 01/09/2026 - 31/08/2028 (24 Months) with an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Renewal: With an option or option(s) to extend for a further 24 months.

CM/PHR/25/5730/02 - Natalizumab for London & SOFE

Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement : 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Options: CM/PHR/25/5730/01 - Lot 1 - Tranche A for North of England and Midlands & East 01/09/2026 - 31/08/2028 (24 Months) with an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Renewal: With an option or option(s) to extend for a further 12 months.

Planning Information

NHS England is advising suppliers of an upcoming tender for the NHS Branded Framework Agreement – Tranche A for the North of England and Midlands & East. Period of Framework Agreement (Lot 1): 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. There will be a separate Lot to provide framework agreement coverage to the London and South of England regions for Natalizumab. The period of Framework Agreement (Lot 2): 1st September 2026 to 31st August 2027 with the option or option(s) to extend for a further 12 months. Eight category areas are covered in Tranche A: Erythropoietin Stimulating Agents, Granulocyte-Colony Stimulating Factor (GCSF), Insulin Analogues, MS Drugs, Parenteral Iron, Severe Asthma, Severe Asthma/Interleukin Inhibitor and Teriparatide. The purpose of this notice is to inform existing and potential new suppliers that if NHS England believe that it would be beneficial a virtual 1:1 preliminary market meeting can be arranged.  Please contact ian.birch1@nhs.net to register your interest. There will also be a 14 day window for queries to be raised via Atamis after all sessions have concluded.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-051c98
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/068603-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£877,670,570 £100M-£1B
Lots Value
£877,670,570 £100M-£1B
Awards Value
£700,702,136 £100M-£1B
Contracts Value
£700,702,136 £100M-£1B

Notice Dates

Publication Date
21 Jul 20261 months ago
Submission Deadline
17 Apr 2026Expired
Future Notice Date
17 Mar 2026Expired
Award Date
15 Jun 20262 months ago
Contract Period
1 Sep 2026 - 31 Aug 2027 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active, Pending
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
25
Supplier Names

ACCORD-UK LTD

AMGEN LIMITED

AVENTIS PHARMA LIMITED t-a Sanofi

BAYER PLC

BIOGEN IDEC LIMITED

CHUGAI PHARMA LIMITED

CIPLA (EU) LIMITED

CST PHARMA LIMITED

ELI LILLY & COMPANY LTD

GEDEON RICHTER (UK) LIMITED

GLAXOSMITHKLINE UK LIMITED

LABORATORIES JUVISE PHARMACEUTICALS

MERCK SERONO LIMITED

MILPHARM LIMITED

NAPP PHARMACEUTICALS LTD

NOVO NORDISK

ORIFARM UK LTD

PFIZER LIMITED

PHARMACOSMOS UK LTD

ROCHE PRODUCTS LIMITED

SANDOZ LIMITED

TEVA UK LIMITED

THORNTON & ROSS LIMITED

VIATRIS UK HEALTHCARE LTD

VIFOR PHARMA UK LTD

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...